DCGO Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

70.16M

-41.94%

-0.138

+245.8%

69.53M

-27.6%

-0.106

+17.73%

71.45M

-11.15%

-0.092

-16.34%

Estimates Revision

The market is revising Upward the revenue expectations for DocGo Inc. (DCGO) for FY2025, with the revenue forecasts being adjusted by 0.19% over the past three months. During the same period, the stock price has changed by -25.49%.

Revenue Estimates for FY2025

Revise Upward

+0.19%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+32.12%

In Past 3 Month

Stock Price

Go Down

-25.49%

In Past 3 Month

4 Analyst Rating

Wall Street analysts forecast DCGO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DCGO is 3.13 USD with a low forecast of 1.50 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

1 Hold

0 Sell

Strong Buy

Current: 0.000

Low

1.50

Averages

3.13

High

4.00

Current: 0.000

Low

1.50

Averages

3.13

High

4.00

Canaccord

Hold

downgrade

2025-11-12

Reason

Canaccord

Price Target

2025-11-12

downgrade

Hold

Reason

Canaccord lowered the firm's price target on DocGo to $1.50 from $1.60 and keeps a Hold rating on the shares. The firm said while the price target does portend upside from current levels they believe that there is some value to be had for DocGo operations however, they do not see multiple expansion from a fundamental perspective until there is meaningful adj-EBITDA loss improvement.

Canaccord

Richard Close

Hold

maintain

2025-08-21

Reason

Canaccord

Richard Close

Price Target

2025-08-21

maintain

Hold

Reason

Canaccord analyst Richard Close raised the firm's price target on DocGo to $1.60 from $1.45 and keeps a Hold rating on the shares. The firm said DocGo showed some progress with its core business in 2Q as it works to replace the waning migrant services contract(s) that should be largely wound down entering 2H;however, there is much work to be done to rightsize the organization while also ramping up new business.

Canaccord

Buy

Hold

downgrade

2025-05-12

Reason

Canaccord

Price Target

2025-05-12

downgrade

Buy

Hold

Reason

Canaccord downgraded DocGo to Hold from Buy with a price target of $1.45, down from $5. While the firm "fully acknowledge that we are late in coming off our Buy rating on shares of DocGo," Canaccord believes it is appropriate to lower its recommendation following a "disappointing" Q1 report and a significant downward revision to 2025 guidance. The "damage is done as it relates to the stock price," adds the firm, which suspects that shares will be range bound for an extended period of time until more clarity and transparency in the business is gained.

Northland

Outperform

downgrade

$6 -> $4

2025-05-12

Reason

Northland

Price Target

$6 -> $4

2025-05-12

downgrade

Outperform

Reason

Northland lowered the firm's price target on DocGo to $4 from $6 and keeps an Outperform rating on the shares. The firm is lowering its FY25 revenue forecast to $311M from $411M and establishing a FY26 revenue forecast at $304M after DocGo announced "a dramatic change," eliminating their government population health business from FY25 forecasts. Federal funding uncertainty cascading to state and local customers has made forecasting unclear, leading management to make the change, the analyst noted.

BTIG

Buy -> Neutral

downgrade

2025-05-09

Reason

BTIG

Price Target

2025-05-09

downgrade

Buy -> Neutral

Reason

BTIG downgraded DocGo to Neutral from Buy without a price target. The company reported "disappointing" Q1 results with a "fairly remarkable reduction" to revenue guidance for 2025, the analyst tells investors in a research note. The firm says the midpoint of the new guidance implies a 50% year-over-year decline in revenue for the year. The reduction was made due to DocGo's decision to remove any non-migrant municipal population health revenue from the guidance given "significant uncertainty" in the municipal channel, driven by ongoing policy changes and budget constraints in Washington D.C., contends BTIG. The firm cites DocGo's "ongoing deterioration in fundamentals, and a consistent lack of visibility" for the downgrade.

Stifel

David Grossman

Buy

downgrade

2025-05-09

Reason

Stifel

David Grossman

Price Target

2025-05-09

downgrade

Buy

Reason

Stifel analyst David Grossman lowered the firm's price target on DocGo to $4 from $5.50 and keeps a Buy rating on the shares. Q1 revenue and non-GAAP EBITDA missed expectations and the company "materially lowered" 2025 guidance, notes the analyst, who points out that the revised range fell "well below" the firm's estimates even though they were "significantly below consensus."

Valuation Metrics

The current forward P/E ratio for DocGo Inc (DCGO.O) is -2.19, compared to its 5-year average forward P/E of 33.39. For a more detailed relative valuation and DCF analysis to assess DocGo Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

33.39

Current PE

-2.19

Overvalued PE

71.71

Undervalued PE

-4.94

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

9.39

Current EV/EBITDA

-1.14

Overvalued EV/EBITDA

17.19

Undervalued EV/EBITDA

1.58

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

1.04

Current PS

0.31

Overvalued PS

1.66

Undervalued PS

0.42

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

DCGO News & Events

Events Timeline

No data

News

1.0

01-05Businesswire

DocGo CFO to Speak at 28th Annual Needham Growth Conference, Advancing Mobile Health Services

7.0

2025-12-18Globenewswire

Halper Sadeh Investigates DocGo Inc. Officers for Potential Fiduciary Breaches

7.0

2025-12-05PRnewswire

DocGo Inc. Under Investigation for Potential Breach of Fiduciary Duties by Officers

People Also Watch

Frequently Asked Questions

What is DocGo Inc (DCGO) stock price today?

The current price of DCGO is 0.8941 USD — it has decreased -1.22 % in the last trading day.

What is DocGo Inc (DCGO)'s business?

DocGo Inc. is a mobile healthcare services company that uses dispatch and communication technology to help provide mobile, in-person medical treatment directly to patients in the comfort of their homes, workplaces and other non-traditional locations and healthcare transportation in major metropolitan cities in the United States and the United Kingdom. The Company’s offerings also include mobile phlebotomy lab services, which is engaged in addressing critical gaps in diagnostic care for underserved populations. The Mobile Health Services include a variety of healthcare services performed at homes, offices and other locations and event services, such as on-site healthcare support at sporting events and concerts. The Transportation Services encompass both emergency response and non-emergency transport services. Non-emergency transport services include ambulance transports and wheelchair transports.

What is the price predicton of DCGO Stock?

What is DocGo Inc (DCGO)'s revenue for the last quarter?

DocGo Inc revenue for the last quarter amounts to 70.81M USD, decreased -48.94 % YoY.

What is DocGo Inc (DCGO)'s earnings per share (EPS) for the last quarter?

DocGo Inc. EPS for the last quarter amounts to -0.28 USD, decreased -660.00 % YoY.

What changes have occurred in the market's expectations for DocGo Inc (DCGO)'s fundamentals?

How many employees does DocGo Inc (DCGO). have?

DocGo Inc (DCGO) has 3404 emplpoyees as of January 10 2026.

What is DocGo Inc (DCGO) market cap?

Today DCGO has the market capitalization of 87.45M USD.